Bioyitech was invited to participate in the 2024 Chinese Association for Research and Advancement of Chinese Medicine
During the conference, Bioyitech showcased its patented animal strain Bifidobacterium animalis subsp. lactis F1-7 and Lactiplantibacillus plantarum F3-2, which focus on metabolic health. These notable probiotic strains have demonstrated significant positive feedback in areas such as glucose and lipid reduction, uric acid control, weight management, alcohol detoxification, liver protection, gut health, emotional well-being and sleep, bone health, immune regulation, blood lipid reduction, as well as anti-inflammatory and anti-aging effects. Each functional claim was supported by targeted mechanism analysis, laboratory data, and publications in top-tier journals, attracting considerable interest and attention from the attending clinical research experts.
Several experts at the conference pointed out that the metabolic functions of probiotics resemble the philosophy of traditional Chinese medicine, which emphasizes preventing and managing diseases through various means. Bioyitech's deep engagement in the metabolic field of probiotics and its ability to deliver end products offer significant insights for traditional Chinese medicine. Experts also noted that the metabolic functions of probiotics share commonalities with integrative medicine, as they achieve comprehensive and robust regulatory effects through multi-target and multi-mechanism actions.
During the exhibition, Professor Shi Dazhuo, President of the New Drug Translation and Clinical Evaluation Subcommittee of the Chinese Association for the Promotion of Traditional Chinese Medicine, Director of the Institute of Cardiovascular Diseases at the Chinese Academy of Traditional Chinese Medicine, and Professor at Peking University Health Science Center and Beijing University of Chinese Medicine, visited the Bioyitech exhibit. He conducted a thorough investigation of Bioyitech's probiotic products and encouraged the company to participate in more clinical trials, so that the pharmaceutical field can better recognize the strength and appeal of Bioyitech's flagship strains.